文摘
摘要目的:探讨髓少突细胞糖蛋白(MOG)经胎盘的传播的免疫球蛋白g从母亲到婴儿和量化孕产妇MOG-IgG期间的系列样品通过测试一个婴儿。
背景:MOG antibody-associated疾病(MOGAD)是一个CNS-inflammatory脱髓鞘疾病发病的年龄中位数的20 - 30年。因此,育龄妇女通常受到影响,和产后可以增加复发的风险。据我们所知,没有报告新生儿MOGAD病例。
设计/方法:我们研究的传播MOG-IgG从母亲到婴儿患者MOGAD MOG-IgG血清阳性的历史。使用一个内部MOG-transfected细胞流式细胞仪测定,我们测量血清中抗体的效价的母亲,脐带血和新生儿在出生时。我们测试了每月的系列样品的孕产妇MOG-IgG量化时间宝贝。
结果:病人于2005年首次开发MOGAD在16岁的时候,当她急性播散性脑脊髓炎的一集。她随后脊髓炎和视神经炎的复发,她收到了血浆置换。她32岁。她没有任何治疗前6周交货。交货前一个月,母亲是阳性MOG-IgG(效价1:20)。在交付,母亲是MOG-IgG负,婴儿和脐带血MOG-IgG阳性(效价1:20)。婴儿又八个月,没有任何MOGAD的临床特征。母亲和婴儿都为阴性MOG-IgG在产后一个月和两个月。
结论:孕产妇MOG-IgG可以被动地转移到胎儿通过胎盘和积极性在婴儿发生尽管低于阈值检测的母亲。MOG-IgG婴儿是短暂的,没有临床表现。
披露:Redenbaugh博士没有披露。约翰·j·陈已收到个人薪酬在5000 - 9999美元的范围为UCB担任顾问。约翰·j·陈已收到个人薪酬在500 - 4999美元的范围为罗氏公司担任顾问。约翰·j·陈已收到个人薪酬在5000 - 9999美元的范围作为顾问。沙根没有披露。Pittock博士已经收到个人薪酬在500 - 4999美元的范围作为顾问基因泰克,Inc . .Pittock博士已经收到个人薪酬在500 - 4999美元的范围作为顾问圣人疗法,Inc . .Pittock博士的机构已收到个人薪酬在500 - 4999美元的范围为阿斯特拉担任顾问。Pittock博士已经收到个人薪酬在500 - 4999美元的范围为主要疗法作为顾问。Pittock博士已经收到个人薪酬在500 - 4999美元的范围作为顾问的联合。 Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedImmune/Viela Bio. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB, Inc. Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman/LaRoche AG. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hofman/LaRoche. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received research support from Grifols. The institution of Dr. Pittock has received research support from NIH. The institution of Dr. Pittock has received research support from Viela Bio/MedImmune/Horizon. The institution of Dr. Pittock has received research support from Alexion Pharmaceuticals. The institution of Dr. Pittock has received research support from F. Hoffman/LaRoche/Genentech. The institution of Dr. Pittock has received research support from NovelMed. The institution of Dr. Pittock has received research support from AstaZeneca. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received research support from Viela Bio. Dr. Flanagan has received research support from UCB. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities.
